Year All2026202520242023202220212020201920182017201620152014 Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies April 01, 2026 Read More Abivax Announces Full Year 2025 Financial Results and Provides Business Updates March 23, 2026 Read More Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 February 21, 2026 Read More Abivax Provides 2026 Corporate Outlook January 07, 2026 Read More Abivax to be Added to Nasdaq Biotechnology Index December 18, 2025 Read More Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings December 17, 2025 Read More Abivax Presents Third Quarter 2025 Financial Results December 15, 2025 Read More Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis November 03, 2025 Read More Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies October 06, 2025 Read More Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data October 05, 2025 Read More
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies April 01, 2026 Read More
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates March 23, 2026 Read More
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 February 21, 2026 Read More
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings December 17, 2025 Read More
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis November 03, 2025 Read More
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies October 06, 2025 Read More
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data October 05, 2025 Read More
